{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:19:48Z","timestamp":1788826788261,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":1371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Previous studies of penile traction therapy (PTT) devices have demonstrated limited\/no efficacy when combined with intralesional therapies for Peyronie\u2019s disease (PD). Recently, randomized data have demonstrated the efficacy of a novel PTT device, RestoreX, developed in cooperation with the Mayo Clinic, in men with PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the safety and efficacy of treatment with the RestoreX device plus collagenase Clostridium histolyticum (CCH) compared with CCH alone and CCH with other PTT devices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective registry has been maintained of all men undergoing CCH injections for PD between March 2014 and January 2019. Assessments were performed at baseline, during each series, and after completion of treatment. Those completing therapy (8 injections or sooner if satisfied) were categorized into group 1 (CCH alone), group 2 (CCH plus any PTT device other than RestoreX), or group 3 (CCH plus RestoreX).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Changes in penile length, curvature, and subjective perception and the occurrence of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 287 men with data on PTT use, 113 had completed therapy with all objective data available and compose the current cohort. Baseline demographic and pathophysiological variables were similar among the 3 groups except penile length and previous PD medications. Following treatment, group 3 demonstrated significantly greater improvements in curvature (mean, 20.3\u00b0\/31% for group 1, 19.2\u00b0\/30% for group 2, and 33.8\u00b0\/49% for group 3), length (-0.7 cm\/-4%, -0.4 cm\/-2%, and\u00a0+1.9 cm\/+17%, respectively), and subjectively estimated curvature improvement (44%, 32%, and 63% respectively), despite shorter daily PTT use (0.9 vs 1.9 hours\/day). Group 3 was more likely than the other groups to experience \u226520\u00b0, \u226520%, and \u226550% curvature improvements, \u22651 cm length gain, and \u226520% length improvement. All results were statistically significant for group 3 versus groups 1 and 2, but not between groups 1 and 2, even after controlling for baseline features and isolating a subset of \u22653 hours\/day PTT use (group 2). Group 3 was 6.9 times more likely to achieve \u226520\u00b0 curvature improvement, and 3.5 times more likely to achieve \u226550% curvature improvement, and 10.7 times more likely to experience \u226520% length improvement. Adverse events were similar among the 3 groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Implications<\/jats:title>\n                    <jats:p>Use of the RestoreX device enhances mean curvature outcomes by 71% and increases penile length in men with PD receiving CCH therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strengths &amp; Limitations<\/jats:title>\n                    <jats:p>Study strengths include a prospective registry, consistent assessments, the largest single-site series with complete posttreatment outcomes reported to date, the largest PTT series reported to date, and a true-to-life clinical design. Limitations include the nonrandomized methodology and single-site setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of RestoreX and CCH is associated with significantly greater curvature and length improvements compared with CCH alone or CCH with other PTT devices.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.jsxm.2019.03.007","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T22:51:23Z","timestamp":1554418283000},"page":"891-900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy of Combined Collagenase\n                    <i>Clostridium histolyticum<\/i>\n                    and RestoreX Penile Traction Therapy in Men with Peyronie\u2019s Disease"],"prefix":"10.1093","volume":"16","author":[{"given":"Manaf","family":"Alom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran L.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Toussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Trost","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , Rochester, MN , USA"},{"name":"Mayo Clinic \u00a0 , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"2023010719011619600_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-662-46753-4_2","article-title":"History and cultural perspective","volume-title":"Penile Augmentation","author":"Kim","year":"2016"},{"key":"2023010719011619600_bib2","first-page":"1259","article-title":"Peyronie's disease and mechanotransduction: An in\u00a0vitro analysis of the cellular changes to Peyronie's disease in a cell-culture strain system","volume":"10","author":"Chung","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"2023010719011619600_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/ncpuro0201","article-title":"Mechanisms of disease: New insights into the cellular and molecular pathology of Peyronie's disease","volume":"2","author":"Gonzalez-Cadavid","year":"2005","journal-title":"Nat Clin Pract Urol"},{"key":"2023010719011619600_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.ijir.3900874","article-title":"Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses","volume":"14","author":"Mulhall","year":"2002","journal-title":"Int J Impot Res"},{"key":"2023010719011619600_bib5","first-page":"2974","article-title":"Myofibroblasts and mechanotransduction: Do forces in the tunica albuginea contribute to Peyronie's disease?","volume":"5","author":"Gelbard","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"2023010719011619600_bib6","first-page":"506","article-title":"Acute phase Peyronie's disease management with traction device: A nonrandomized prospective controlled trial with ultrasound correlation","volume":"11","author":"Martinez-Salamanca","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"2023010719011619600_bib7","first-page":"558","article-title":"Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease: Results of a phase II prospective study","volume":"6","author":"Gontero","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"2023010719011619600_bib8","first-page":"1468","article-title":"Penile traction therapy for treatment of Peyronie's disease: A single-center pilot study","volume":"5","author":"Levine","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"2023010719011619600_bib9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bju.14602","article-title":"Penile traction therapy with the new device \u201cPenimaster PRO\u201d is effective and safe in the stable phase of Peyronie's disease: A controlled multicenter study","volume":"123","author":"Moncada","year":"2019","journal-title":"BJU Int"},{"key":"2023010719011619600_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.urology.2018.07.039","article-title":"The effect of adjunct mechanical traction on penile length in men undergoing primary treatment for Peyronie's disease: A systematic review and meta-analysis","volume":"122","author":"Haney","year":"2018","journal-title":"Urology"},{"key":"2023010719011619600_bib11","first-page":"754","article-title":"The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie disease","volume":"194","author":"Yafi","year":"2015","journal-title":"J\u00a0Urol"},{"key":"2023010719011619600_bib12","first-page":"288","article-title":"Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie\u2019s disease","volume":"9","author":"Abern","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"2023010719011619600_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","article-title":"Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease","volume":"104","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"key":"2023010719011619600_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000000245","article-title":"Outcomes of a novel penile traction device (RestoreX) in men with Peyronie\u2019s disease: A randomized, single-blinded, controlled trial","author":"Ziegelmann","year":"2019","journal-title":"Submitted J Urol Jan"},{"key":"2023010719011619600_bib15","first-page":"1051","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie's disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J\u00a0Urol"},{"key":"2023010719011619600_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","article-title":"Plaque calcification: An important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie's disease","volume":"119","author":"Wymer","year":"2018","journal-title":"Urology"},{"key":"2023010719011619600_bib17","first-page":"199","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J\u00a0Urol"},{"key":"2023010719011619600_bib18","first-page":"2396","article-title":"A\u00a0retrospective comparative study of traction therapy vs no traction following tunica albuginea plication or partial excision and grafting for Peyronie's disease: Measured lengths and patient perceptions","volume":"9","author":"Rybak","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"2023010719011619600_bib19","first-page":"2268","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J\u00a0Urol"},{"key":"2023010719011619600_bib20","first-page":"1472","article-title":"Sildenafil 25 mg ODT\u00a0+ collagenase clostridium hystoliticum vs collagenase Clostridium hystoliticum alone for the management of Peyronie\u2019s disease: A matched-pair comparison analysis","volume":"15","author":"Cocci","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"2023010719011619600_bib21","author":"Ralph DJ, Abdel Raheem A, Liu G. Treatment of Peyronie\u2019s disease with collagenase Clostridium histolyticum and vacuum therapy: A randomized, open-label pilot study. J Sex Med;14:1430\u20131437."},{"key":"2023010719011619600_bib22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/andr.12497","article-title":"Collagenase Clostridium histolyticum for the treatment of Peyronie\u2019s disease: A prospective Italian multicentric study","volume":"6","author":"Capece","year":"2018","journal-title":"Andrology"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519304321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519304321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/6\/891\/48476999\/jsm_16_6_891.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/6\/891\/48476999\/jsm_16_6_891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T14:01:56Z","timestamp":1673100116000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/16\/6\/891\/6966767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,4,4]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.03.007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735506211.793574540","asserted-by":"object"}]},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,4,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.","name":"copyright","label":"Copyright"}]}}